Absci

Absci is a generative AI drug creation company that is revolutionizing the biopharma and biotechnology industries. With its slogan "Creating Drugs at the Speed of Ai," Absci combines AI with scalable wet lab technologies to create better biologics for patients, faster. The company's Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. Founded in 2011 and headquartered in the United States, Absci has recently secured a substantial $86.40M Post-IPO Equity investment at 27 February 2024.

Absci's innovative approach allows it to screen billions of cells per week, enabling the transition from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. This streamlined process holds the promise of delivering breakthrough therapeutics at the click of a button, for everyone. As a content writer and startup analyst, it's evident that Absci's disruptive technology and recent investment underscore the confidence and interest from the investment community in its potential to revolutionize drug discovery and development.